Psoriasis treatment 2003 at the new millennium: Position paper on behalf of the authors

Journal of the American Academy of Dermatology

Volumn 49, Issue 2 A, 2003, Pages

  Menter, M Alan ^a   Krueger, Gerald C ^a   Feldman, Steven R ^a   Weinstein, Gerald D ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; ANTIPSORIASIS AGENT; BASILIXIMAB; BEXAROTENE; BIRB 796 BS; CYCLOSPORIN A; EFALIZUMAB; ETANERCEPT; ETRETIN; ETRETINATE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; IR 502; ISI 104838; ISIS 104838; METHOTREXATE; METHOXSALEN; ONERCEPT; PIMECROLIMUS; RETINOID; SIPLIZUMAB; SORITANE; TAZAROTENE; UNCLASSIFIED DRUG; ZORCELL;

CROHN DISEASE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MANAGED CARE; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; PUVA; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN DISEASE; TREATMENT INDICATION;

EID: 0041632271     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/mjd.2003.545     Document Type: Review

References (9)

1. Menter A, Saporito F. Methotrexate and psoriasis in the era of new biologic agents. J Am Acad Dermatol (in press).
2. Bernhard JD. Commentary on oral methoxsalen photochemotherapy for the treatment of psoriasis: A cooperative clinical trial: From napkin to notabilia. J Invest Dermatol 1989;92:154S-156S.
3. Mueller W, Hermann B. Cyclosporin for psoriasis. N Engl J Med 1979;301:555.
4. Liem WH, McCullough JL, Weinstein GD. Effectiveness of topical therapy for psoriasis: results of a national survey. Cutis 1995;55: 306-10.
5. Morris LF, Harrod MJ, Menter M, Silverman AK. Methotrexate and reproduction in men: case report and recommendations. J Am Acad Dermatol 1993;29:913-6.
6. Griffiths CE, Clark CM, Chalmers RJ, Li Wan Po A, Williams HC. A systemic review of treatments for severe psoriasis. Health Technol Assess 2000;4:1-125.
7. Krueger GG, Feldman ST, Camisa C, Duvic M, Elder J, Gottlieb A, et al. Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000;43:281-5.
8. Koo J, Menter A, Lebwohl M, Kozma C, Slaton T, Wojcik A, Kowalski J. The relationship between quality of life and disease: results from a large cohort of mild, moderate, and severe psoriasis patients (abstract). Br J Dermatol 2002;147:1078.
9. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 national Psoriasis Foundation patient-membership survey (comment). Arch Dermatol 2001;137:280-4.